Evidence map›Paper›PMID 40454502›Full record

SynthesisMini reviews in medicinal chemistry2025

Innovations in Cannabis Delivery Systems: A Patent Review (2012-2024).

Ana Sofia Guerrero Casas, Vanessa Castro Felix Lima, Nicolas Redondo, Izabel Almeida Alves, Diana Marcela Aragon

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Mini reviews in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ana Sofia Guerrero CasasDepartamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia.
Vanessa Castro Felix LimaPrograma de Pós-Graduação em Farmácia, Universidade Estadual da Bahia, Salvador, Bahia, Brasil, Brazil.
Nicolas RedondoDepartamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia.
Izabel Almeida AlvesPrograma de Pós-Graduação em Farmácia, Universidade Estadual da Bahia, Salvador, Bahia, Brasil, Brazil.ORCID 0000-0002-8935-6542
Diana Marcela AragonDepartamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCannabis sativa has been cultivated for over 11,700 years, originating in Central and Southeast Asia, and has been used for medical, recreational, and religious purposes. Among its therapeutic potentials, it is notable for its capacity to alleviate pain, nausea, anxiety, and more. The plant's primary secondary metabolites are cannabinoids, which interact with the endocannabinoid system to produce these effects. However, due to the dosage variability and the secondary effects associated with a lack of targeted action, their medical use is limited, creating the need for effective delivery systems. METHODOLOGY: This systematic patent review on cannabis drug delivery systems was conducted using patents retrieved from the Espacenet database. The search employed the keywords "Cannabis" and "Delivery," along with the IPC classification code A61, to filter patents filed between 2012 and 2024. This initial search yielded 99 patents, which were further screened to identify 15 patents that met the inclusion criteria.

resultsOf the selected patents, most originated from the United States, followed by Canada, international patents (WIPO), and China. A notable increase in patent filings occurred in 2022, coinciding with the peak in scientific publications on the topic. This trend indicates a growing interest in the design of cannabis delivery systems. DISCUSSION: The historical importance and therapeutic potential of Cannabis sativa are welldocumented, yet modern medical use remains restricted due to pharmacokinetic limitations. Delivery systems such as extracellular vesicles, microneedles, and emulsions have been developed to improve the bioavailability and stability of cannabinoids. Extracellular vesicles facilitate targeted, noninvasive delivery of cannabinoids to the central nervous system. Microneedles offer a painless method for transdermal administration, overcoming skin barrier limitations. Emulsions improve the solubility and bioavailability of lipophilic cannabinoids, making them suitable for various administration routes.

conclusionSince 2012, there has been considerable growth in patents and publications related to cannabis drug delivery systems, driven by the therapeutic potential of cannabinoids. Innovations in delivery systems like emulsions, microneedles, and extracellular vesicles aim to improve the pharmacokinetics and therapeutic efficacy of cannabis-derived compounds, representing a shift towards medical cannabis applications.

Indexed as

CannabinoidsCannabisDrug Delivery SystemsPatents as TopicAnimalsHumansCannabinoidsCannabis sativadrug deliverylipophilic cannabinoidsnervous system.Patentsphytocannabinoids

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.